Literature DB >> 8207990

Secondary chromosomal abnormalities in acute leukemias.

B Johansson1, F Mertens, F Mitelman.   

Abstract

Secondary chromosomal aberrations reported in the literature were surveyed in acute myeloid or lymphoblastic leukemia (AML or ALL) with one of the following primary abnormalities: in AML, t(1;3), t(1;22), der(1;7), inv(3), t(3;5) +4, del(5q), t(6;9), -7, t(7;11), del(7q), +8, t(8;16), t(8;21), +9, t(9;11), del(9q), t(9;22), +11, del(11q), t(11;19), del(12p), +13, t(15;17), inv(16), t(16;21), i(17)(q10), del(20q), -21, +21, +22, and -Y; in ALL, t(1;14), t(1;19), der(19)t(1;19), t(4;11), del(6q), t(8;14)(q24;q11), t(8;14)(q24;q32), t(8;22), del(9p), dic(9;12), i(9)(q10), t(9;22), t(10;14), t(11;14), t(11;19), del(12p), -20, +21, and del(22q). Out of 7111 acute leukemias with clonal karyotypic aberrations, 2414 AMLs and 1078 ALLs had one of the selected primary chromosome rearrangements, and 40 and 49% of these AMLs and ALLs, respectively, displayed additional abnormalities. The type and frequency of these secondary changes were ascertained and then correlated with both the primary abnormality and the morphology or immunophenotype of the acute leukemia. The distribution of the secondary changes was clearly nonrandom. The most frequent numerical changes were -Y, -X, -7, +8, and +22 in AML and +X, +6, -7, +8, and +21 in ALL. The most common structural aberrations were del(5q), del(7q), and del(9q) in AML and dup(1q), i(7q)(q10), and der(22)t(9;22) in ALL. Some secondary changes were common to both disease groups, e.g. -7, +8, and +21, but several anomalies were restricted to either AML, such as -X, -5, and del(9q), or ALL, e.g. +X, i(7)(q10), and i(9)(q10). The type and frequency of the secondary aberrations varied within the AMLs and ALLs, not only among the different primary abnormality subgroups but also among the AML morphologies and the immunophenotypic maturation degrees of the ALLs. In general, the type of primary abnormality, rather than the differentiation stage of the acute leukemia, appeared to be instrumental in determining the type of secondary changes accruing. This conclusion was based on the finding that several primary abnormalities characterizing acute leukemias of the same morphology or immunophenotype displayed different patterns of secondary anomalies. The nonrandom, and sometimes quite specific, patterns of secondary aberrations strongly indicate that they are responsible for important phenotypic features of the tumor cell population, presumably closely associated with tumor progression. The molecular pathogenetic consequences of the secondary anomalies are unknown, but since most secondary changes are monosomies, trisomies, deletions, or isochromosomes resulting in genomic imbalances, one may hypothesize that gene dosage alterations rather than specific gene rearrangements are essential for tumor evolution.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8207990

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  9 in total

1.  Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma.

Authors:  Sabine Franke; Iwona Wlodarska; Brigitte Maes; Peter Vandenberghe; Ruth Achten; Anne Hagemeijer; Chris De Wolf-Peeters
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Additional chromosome 1q aberrations and der(16)t(1;16), correlation to the phenotypic expression and clinical behavior of the Ewing family of tumors.

Authors:  B Stark; C Mor; M Jeison; R Gobuzov; I J Cohen; Y Goshen; J Stein; S Fisher; S Ash; I Yaniv; R Zaizov
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Acute myelomonocytic leukemia with dysplastic bone marrow eosinophils showing t(5;17)(q13;q11) and a secondary chromosomal aberration, inv(16)(p13q22).

Authors:  Rika Sakai; Katsumichi Fujimaki; Etsuko Yamazaki; Hiroshi Sakamoto; Heiwa Kanamori; Ikuo Miura; Yoshiaki Ishigatsubo
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

4.  Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice.

Authors:  D B Zimonjic; J L Pollock; P Westervelt; N C Popescu; T J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

Review 5.  Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.

Authors:  Luke F Peterson; Anita Boyapati; Eun-Young Ahn; Joseph R Biggs; Akiko Joo Okumura; Miao-Chia Lo; Ming Yan; Dong-Er Zhang
Journal:  Blood       Date:  2007-04-05       Impact factor: 22.113

6.  Computer aided analysis of additional chromosome aberrations in Philadelphia chromosome positive acute lymphoblastic leukaemia using a simplified computer readable cytogenetic notation.

Authors:  Jutta Bradtke; Harald Balz; Christa Fonatsch; Barbara Heinze; Anna Jauch; Brigitte Mohr; Claudia Schoch; Harald Rieder
Journal:  BMC Bioinformatics       Date:  2003-01-28       Impact factor: 3.169

7.  Increased μ-Calpain Activity in Blasts of Common B-Precursor Childhood Acute Lymphoblastic Leukemia Correlates with Their Lower Susceptibility to Apoptosis.

Authors:  Anna Mikosik; Izabella Henc; Katarzyna Ruckemann-Dziurdzińska; Joanna E Frąckowiak; Anna Płoszyńska; Anna Balcerska; Ewa Bryl; Jacek M Witkowski
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

8.  Mutation, methylation, and gene expression profiles in dup(1q)-positive pediatric B-cell precursor acute lymphoblastic leukemia.

Authors:  Rebeqa Gunnarsson; Sebastian Dilorenzo; Kristina B Lundin-Ström; Linda Olsson; Andrea Biloglav; Henrik Lilljebjörn; Marianne Rissler; Per Wahlberg; Anders Lundmark; Anders Castor; Mikael Behrendtz; Thoas Fioretos; Kajsa Paulsson; Anders Isaksson; Bertil Johansson
Journal:  Leukemia       Date:  2018-03-12       Impact factor: 11.528

9.  The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm.

Authors:  Aishwarya Ravindran; Rong He; Rhett P Ketterling; Majd D Jawad; Dong Chen; Jennifer L Oliveira; Phuong L Nguyen; David S Viswanatha; Kaaren K Reichard; James D Hoyer; Ronald S Go; Min Shi
Journal:  Blood Cancer J       Date:  2020-01-23       Impact factor: 11.037

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.